Hosted on MSN1d
New Criteria Developed for Appropriate Use of Amyloid, Tau PET
Appropriate use criteria (AUC) for the use of amyloid and tau positron emission tomography (PET) have been issued by the ...
WebMD1d
Has Our Dementia Risk Doubled? Don’t Panic – Here’s What to Do
Recent headlines suggest that up to 42% of people ages 55 and older face an eventual dementia diagnosis. But some experts have a follow-up message: Risk isn't the same as destiny, and there are ways ...
New criteria developed for appropriate use of cognitive impairment imaging tools
Appropriate use criteria (AUC) for the use of amyloid and tau positron emission tomography (PET) have been issued by the ...
News Medical1d
New probes offer insight into cholesterol's role in Alzheimer's disease
The search for answers to Alzheimer's disease and other neurodegenerative disorders remains one of the most pressing goals in brain research. Maciej J. Stawikowski, Ph.D., an assistant professor of ...
Neuraly and Enigma Biomedical USA announce a Research License and Commercialization Option Agreement for PET Imaging Biomarker, PMI04
On January 16, 2025, Neuraly Inc. (Neuraly), a wholly owned subsidiary of D&D Pharmatech Inc., and Enigma Biomedical USA, Inc. (Enigma) announced the signing of a research license and ...
News Medical on MSN3d
Spear Bio secures FDA breakthrough device designation for its novel pTau 217 blood test, advancing scalable solutions for early Alzheimer's disease diagnosis
Spear Bio Inc., a biotechnology company pioneering next-generation ultra-sensitive immunoassays, today announced that its pTau 217 blood test has been granted Breakthrough Device Designation by the U.
Medscape3d
Updated Alzheimer’s Guidelines Chart the Full Diagnostic Journey
Expanded clinical practice guidelines aim to empower all clinicians, regardless of specialty or practice setting to evaluate ...
Strategic Acquisition of Life Molecular Imaging Bolsters Lantheus’s Position in Alzheimer’s Diagnostic Market
Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on LNTH stock, giving a Buy rating yesterday.Stay Ahead of the ...
Strategic Acquisition of Life Molecular Imaging Boosts Lantheus’ Position in Alzheimer’s Radiodiagnostic Market
Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on LNTH stock, giving a Buy rating yesterday.Stay Ahead of the ...
Daily Independent4d
With severe dementia, medications are of limited benefit
The doctor said his pulse rate is low, and the medications have a tendency to lower the pulse even more, which can be dangerous. His Alzheimer's stage is 4-5, and his MMSE score was 5 out of 30. Is ...
Up to 4 in 10 people could develop dementia after 55. What you can do to lower your risk
The new estimate is based on a new study that found a higher lifetime risk than previously thought: After age 55, people have ...